natgillin/translations-raw huggingface dataset:
Patients whose blood glucose control is greatly improved e.g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly.
Bolnikom, ki se jim kontrola glukoze v krvi možno izboljša npr. z intenzivnim insulinskim zdravljenjem, se lahko spremenijo običajni opozorilni simptomi hipoglikemije, zato jim moramo ustrezno svetovati.
Patients whose blood glucose control is greatly improved e.g. by intensified insulin therapy, may experience a change in their usual warning symptoms of hypoglycaemia and should be advised accordingly.
Bolnikom, ki se jim uravnanost glukoze v krvi zelo izboljša, npr. z intenziviranim insulinskim zdravljenjem, se obicajni opozorilni simptomi hipoglikemije lahko spremenijo in jih je s to možnostjo treba seznaniti.
patients whose blood glucose levels are not satisfactorily controlled by the maximum tolerated dose of metformin alone;
bolnikih, pri katerih ravni glukoze v krvi niso zadostno uravnane z največjim odmerkom samostojnega metformina, ki ga še lahko prenašajo;
Patients whose blood-glucose control is greatly improved (e.g. by intensified insulin therapy) may experience a change in their usual warning symptoms of hypoglycaemia and must be advised accordingly.
Bolnikom, ki se jim uravnanost glikemije zelo izboljša (npr. z intenziviranim insulinskim zdravljenjem), se običajni opozorilni simptomi hipoglikemije lahko spremenijo in jih je s to možnostjo treba seznaniti.
Patients whose blood-glucose control is greatly improved (e.g. by intensified therapy) may experience a change in their usual warning symptoms of hypoglycaemia, and must be advised accordingly.
Bolnikom, pri katerih se urejenost glikemije zelo izboljša (npr. z intenziviranim zdravljenjem), se običajni opozorilni simptomi hipoglikemije lahko spremenijo in jih je s to možnostjo treba seznaniti.
patients whose bones are still growing such as children and adolescents.
bolnikih, katerih kosti še vedno rastejo, kot so otroci in mladostniki.
Patients whose disease progresses during or shortly after treatment with crizotinib currently have very limited treatment options and therefore a high unmet clinical need.
Bolniki, pri katerih bolezen med ali kmalu po zdravljenju s krizotinibom napreduje, imajo trenutno le malo možnosti za zdravljenje in s tem veliko neizpolnjeno klinično potrebo.
Patients whose dose of Ribavirin BioPartners is reduced to 600 mg daily receive one 200 mg tablet in the morning and two 200 mg tablets in the evening.
Bolniki, katerih odmerek zdravila Ribavirin BioPartners je zmanjšan na 600 mg na dan, naj prejmejo po eno 200 mg tableto zjutraj in dve 200 mg tableti zvečer.
Patients whose dose of Ribavirin Teva Pharma B.V. is reduced to 600 mg daily receive one 200 mg tablet in the morning and two 200 mg tablets in the evening.
Bolniki, katerih odmerek zdravila Ribavirin Teva Pharma B.V. je zmanjšan na 600 mg na dan, naj prejmejo po eno 200 mg tableto zjutraj in dve 200 mg tableti zvečer.
Patients whose initial dose is 100 micrograms and who need to titrate to a higher dose due to a lack of effect can be instructed to use two 100 microgram sprays (one in each nostril) for their next BTP episode.
Bolnikom, katerih začetni odmerek je 100 mikrogramov in ki se morajo zaradi pomanjkanja učinka titrirati na večji odmerek, lahko naročimo, naj pri naslednji epizodi BTP uporabijo dva 100-mikrogramska vpiha (po enega v vsako nosnico).
Patients whose menstrual bleeding became normal (PBAC <
Bolnice, pri katerih je menstruacijska krvavitev postala normalna (PBAC < 75) v
Patients whose vision gets better and stays better should not receive any more implants.
Bolniki, ki se jim je vid popravil in se ne slabša, vsadkov ne smejo več prejeti.
Patients whose vision is getting worse and is not improved by Ozurdex should also not receive any more implants.
Bolniki, ki se jim vid slabša in se jim z uporabo zdravila Ozurdex ni popravil, prav tako ne smejo prejeti dodatnih vsadkov.
Patients will also receive from their doctor an alert card summarising key safety information on the medicine.
Bolniki morajo od zdravnika prejeti tudi opozorilno kartico, ki povzema ključne informacije o varnosti zdravila.
Patients will be carefully checked by their doctor for signs of this infection before treatment is started. if you have low counts of red blood cells (anaemia), white blood cells and platelets, or blood clotting problems before starting the treatment, or if you develop them during treatment.
Pred začetkom zdravljenja bo zdravnik bolnike skrbno pregledal glede znakov te okužbe. če imate majhno število eritrocitov (anemijo), levkocitov in trombocitov, če imate težave s strjevanjem krvi pred začetkom zdravljenja, ali če se takšne težave pojavijo med zdravljenjem.
Patients will be carefully checked by their doctor for signs of this infection before treatment is started. if you have low counts of red blood cells (anaemia), white blood cells and platelets, or blood clotting problems before starting the treatment, or if you develop them during treatment.
Pred začetkom zdravljenja bo zdravnik bolnike skrbno pregledal glede znakov te okužbe. če imate pred začetkom zdravljenja majhno število rdečih krvnih celic (anemija), belih krvnih celic in krvnih ploščica ali težave s strjevanjem krvi, ali če se to razvije med zdravljenjem.
Patients will be carefully checked by their doctor for signs of this infection before treatment is started. if you have low counts of red blood cells (anaemia), white blood cells and platelets, or blood clotting problems before starting the treatment, or if you develop them during treatment.
Pred začetkom zdravljenja mora zdravnik natančno preveriti, ali ima bolnik znake te okužbe. če imate majhno število eritrocitov (anemija), levkocitov in trombocitov, če imate težave s strjevanjem krvi pred začetkom zdravljenja, ali če se takšne težave pojavijo med zdravljenjem.
Patients will be given a special patient alert card with safety information that patients should carry on them.
Bolniki bodo prejeli posebno opozorilno kartico z informacijami o varnosti zdravila, ki jo morajo imeti vedno pri sebi.
Patients will not be required to have a fresh tissue biopsy to determine RET status before enrolment.
Za določitev statusa RET pred vključitvijo pri bolnikih ne bo zahtevano opraviti sveže biopsije tkiva.
Patients with 4+ nodes
Starostniki
Patients with 6-month SAD (95% CI)
Bolniki s 6-mesečnim SAD (95-odstotni IZ)
Patients with a baseline performance score ≥ 2, active brain metastases or autoimmune disease, and patients who had been receiving systemic immunosuppressants prior to study entry were excluded from the clinical trials of nivolumab or nivolumab in combination with ipilimumab.
Bolnike z izhodiščno oceno telesne zmogljivosti ≥ 2, aktivnimi zasevki v možganih ali avtoimunsko boleznijo ter bolnike, ki so se pred vključitvijo v študijo zdravili s sistemskimi imunosupresivi, so iz kliničnih preskušanj nivolumaba ali nivolumaba v kombinaciji z ipilimumabom izključili.
Patients with a baseline viral load > 100,000 HIV-1 RNA copies/mL who experienced virologic failure exhibited a higher rate of treatment emergent resistance to the NNRTI class.
Bolniki z začetno virusno obremenitvijo > 100,000 HIV-1 RNA kopij/ml, pri katerih se je pojavil virološki neuspeh, so imeli višjo stopnjo rezistence na NNRTI, nastale med zdravljenjem.
Patients with a baseline viral load > 100,000 HIV-1 RNA copies/mL who experienced virologic failure exhibited a higher rate of treatment emergent resistance to the NNRTI class.
Bolniki z začetno virusno obremenitvijo > 100.000 HIV-1 RNA kopij/ml, pri katerih se je pojavil virološki neuspeh, so imeli višjo stopnjo rezistence na NNRTI, nastale med zdravljenjem.
Patients with a body mass index (BMI) greater than 30 kg/m2 may be at increased risk of abnormal wound healing based on data from the medical literature.
Podatki iz medicinske literature kažejo, da utegne biti pri bolnikih, ki imajo indeks telesne mase (BMI) večji od 30 kg/m2, tveganje nenormalnega celjenja ran večje.
Patients with a body surface area greater than 1.5 m2 may be prescribed Myclausen capsules at a dose of 1 g twice daily (2 g daily dose).
Pacientom, katerih telesna površina je večja od 1,5 m2 lahko predpišemo Myclausen kapsule v odmerku 1 g dvakrat na dan (dnevni odmerek 2 g).
Patients with a body surface area greater than 1.5 m2 may be prescribed Mycophenolate mofetil Teva capsules at a dose of 1 g twice daily (2 g daily dose).
Bolnikom s telesno površino nad 1,5 m2 predpišemo kapsule zdravila Mofetilmikofenolat Teva v odmerku 1 g dvakrat na dan (dnevni odmerek 2 g).
Patients with a body surface area greater than 1.5 m2 may be prescribed Myfenax capsules at a dose of 1 g twice daily (2 g daily dose).
Bolnikom s telesno površino nad 1,5 m2 predpišemo kapsule zdravila Myfenax v odmerku 1 g dvakrat na dan (dnevni odmerek 2 g).
Patients with a body surface area of 1.25 to 1.5 m2 may be prescribed Myclausen capsules at a dose of 750 mg twice daily (1.5 g daily dose).
Pacientom, katerih telesna površina je od 1,25 do 1,5 m2 lahko predpišemo kapsule Myclausen v odmerku 750 mg dvakrat dnevno (dnevni odmerek 1,5 g).
Patients with a body surface area of 1.25 to 1.5 m2 may be prescribed Myfenax capsules at a dose of 750 mg twice daily (1.5 g daily dose).
Bolnikom s telesno površino med 1,25 in 1,5 m2 predpišemo kapsule zdravila Myfenax v odmerku 750 mg dvakrat na dan (dnevni odmerek 1,5 g).
Patients with a cancer of the blood (chronic lymphocytic leukaemia) that leads to a lack of antibody production and recurrent infections when preventative antibiotics have failed.
Bolniki s krvnim rakom (kronično limfocitno levkemijo), ki povzroči prenehanje nastajanja protiteles in ponavljajoče se okužbe, ki jih ne preprečijo preventivni antibiotiki.
patients with a certain kind of blood cancer (chronic lymphocytic leukaemia) which leads to a lack of antibody production and recurrent infections when preventative antibiotics have failed.
bolniki z določeno vrsto krvnega raka (kronično limfocitno levkemijo), ki povzroči pomanjkanje tvorbe protiteles in ponavljajoče se okužbe, ko je bilo preventivno antibiotično zdravljenje neuspešno,
patients with a condition that could lead to body tissues being deprived of oxygen (e.g. heart or respiratory failure) patients who have liver impairment or are suffering from alcoholism or are intoxicated.
bolnikih z boleznijo, ki lahko povzroči, da telesna tkiva ne dobijo dovolj kisika (npr. srčno ali respiratorno popuščanje); bolnikih, ki imajo okvaro jeter, trpijo za alkoholizmom ali so pod vplivom alkohola.
Patients with a creatinine clearance above 50 ml/min require no reduction in daily dose or dosing frequency.
Pri bolnikih s kreatininskim očistkom več kot 50 ml/min ni treba zmanjšati dnevnega odmerka ali pogostnosti odmerjanja.
Patients with a current or previous diagnosis of bulimia or anorexia nervosa
Bolniki, ki imajo trenutno ali so imeli v preteklosti diagnozo bulimije ali anoreksije nervoze
Patients with a current seizure disorder or a history of seizures (see section 4.4)
Bolniki, ki imajo trenutno konvulzivne motnje ali so imeli v preteklosti epileptične napade (glejte poglavje 4.4)
Patients with a Day 43 bleeding assessment, n
Bolniki, pri katerih je bila na 43. dan ocenjena krvavitev, n
Patients with a femoral epiphyseal growth plate that is not fully closed.
Bolniki s femoralno epifizo rastne ploščice, ki se še ni povsem zaprla.
Patients with a high anti-JCV antibody index who have received more than 2 years of TYSABRI therapy and without prior history of immunosuppressant therapy.
Bolnike z visokim indeksom protiteles proti JCV, ki so se z zdravilom TYSABRI zdravili več kot 2 leti in se pred tem niso zdravili z imunosupresivi.
Patients with a high tumour burden and/or a high circulating lymphocyte count (> 25 x 109/L) and/or renal impairment (CrCl <70 mL/min) are considered at risk of TLS and should receive prophylaxis.
Bolniki z velikim tumorskim bremenom in/ali velikim številom limfocitov v krvnem obtoku (> 25 x 109/l) in/ali ledvično okvaro (očistek kreatinina < 70 ml/min) imajo večje tveganje za sindrom razpada tumorja in morajo prejeti profilakso.
Patients with a high tumour burden or with a high number (≥25 x 109/L) of circulating malignant cells such as patients with CLL, who may be at higher risk of especially severe cytokine release syndrome, should be treated with extreme caution.
Bolnike z veliko tumorsko maso ali velikim številom (≥ 25 x 109/l) krožečih malignih celic, kot so bolniki s KLL, pri katerih obstaja večje tveganje izjemno hudega sindroma sproščanja citokinov, zdravimo izjemno pazljivo.
Patients with a high tumour burden or with a high number (≥25 x 109/L) of circulating malignant cells, such as patients with CLL who may be at higher risk of especially severe cytokine release syndrome, should be treated with extreme caution.
Bolnike z velikim tumorskim bremenom ali velikim številom (≥ 25 x 109/l) malignih celic v krvnem obtoku, kot so bolniki s KLL, ki imajo morda večje tveganje za posebno hud sindrom sproščanja citokinov, je treba zdraviti izjemno pazljivo.
Patients with a high tumour burden or with a high number (≥25 x 109/L) of circulating malignant cells, who may be at higher risk of especially severe cytokine release syndrome, should be treated with extreme caution.
Bolnike z velikim tumorskim bremenom ali velikim številom (≥ 25 x 109/l) malignih celic v krvnem obtoku, ki imajo morda večje tveganje za posebno hud sindrom sproščanja citokinov, je treba zdraviti izjemno pazljivo.
Patients with a high tumour burden should be considered to be at greater risk for TLS.
Tveganje za sindrom lize tumorja je večje pri bolnikih z velikim tumorskim bremenom.
Patients with a history of a Whipple procedure have a higher risk of serious infections following ONIVYDE in combination with 5-FU and leucovorin (see section 4.8).
Bolniki, ki so prestali Whipplovo operacijo, imajo po zdravljenju z zdravilom ONIVYDE v kombinaciji s 5-FU in levkovorinom večje tveganje za resne okužbe (glejte poglavje 4.8).
Patients with a history of bipolar disorder
Bolniki z bipolarno motnjo v anamnezi
patients with a history of certain disorders of the immune system, or who have had an organ transplant and are taking medicines that suppress the immune system, children and adolescents with a history of severe mental illness, particularly severe depression, suicidal thoughts or suicide attempts.
bolnikih, ki imajo določene motnje imunskega sistema v anamnezi ali so imeli presaditev organa in jemljejo zdravilo za zaviranje delovanja imunskega sistema, otrocih in mladostnikih z anamnezo hude duševne bolezni, še posebej hude depresije, samomorilnih misli ali poskusa samomora.
Patients with a history of CHF showed a higher incidence of ventricular arrhythmia in the first two hours post dose (7.3% for BRINAVESS compared to 1.6% in placebo).
Pri bolnikih z anamnezo kongestivnega srčnega popuščanja je bila v prvih dveh urah po odmerku pojavnost prekatnih motenj srčnega ritma večja (7,3 % z zdravilom BRINAVESS in 1,6 % s placebom).
Patients with a history of colonisation with organisms such as Burkholderia cenocepacia, Burkholderia dolosa, or Mycobacterium abscessus or who had 3 or more abnormal liver function tests (ALT, AST, AP, GGT ≥3 times the ULN or total bilirubin ≥2 times the ULN) were excluded.
Bolnike z anamnezo kolonizacije z mikroorganizmi, kot so Burkholderia cenocepacia, Burkholderia dolosa ali Mycobacterium abscessus, ali ki so imeli 3 ali več nenormalnih testov funkcije jeter (ALT, AST, AP, GGT ≥3-krat ULN ali celotni bilirubin ≥2- krat ULN), so izključili.
Patients with a history of decreased pulmonary function may be at a greater risk for pulmonary complications from severe reactions and should be monitored closely during infusion of ofatumumab.
Bolniki z anamnezo zmanjšane pljučne funkcije imajo lahko večje tveganje pljučnih zapletov zaradi hudih reakcij, zato jih je treba med infundiranjem ofatumumaba natančno kontrolirati.
Patients with a history of hypersensitivity to infliximab (see section 4.8), to other murine proteins, or to any of the excipients listed in section 6.1.
Bolniki z anamnezo preobčutljivosti na infliksimab (glejte poglavje 4.8), druge glodalske beljakovine ali katero koli pomožno snov, navedeno v poglavju 6.1.
Patients with a history of hypersensitivity to infliximab (see section 4.8), to other murine proteins, or to any of the excipients listed in section 6.1.
Bolniki z anamnezo preobčutljivosti na infliksimab (glejte poglavje 4.8), druge glodavske beljakovine ali katero koli pomožno snov, navedeno v poglavju 6.1.
Patients with a history of hypersensitivity to natural or recombinant interferon beta or to any excipients listed in section 6.1.
Pri bolnikih, ki so že imeli preobčutljivostno reakcijo na naravni ali rekombinantni interferon-β ali katero koli pomožno snov, navedeno v poglavju 6.1.
Patients with a history of hypersensitivity to natural or recombinant interferon beta, human albumin or to any excipients listed in section 6.1.
Pri bolnikih, ki so že imeli preobčutljivostno reakcijo na naravni ali rekombinantni interferon-β, humani albumin ali katero koli pomožno snov, navedeno v poglavju 6.1.
Patients with a history of hypersensitivity to natural or recombinant interferon beta, human albumin or to any of the excipients listed in section 6.1.
bolniki z znano preobčutljivostjo na naravni ali rekombinantni interferon beta, humani albumin ali katero koli pomožno snov, navedeno v poglavju 6.1
Patients with a history of hypersensitivity to talimogene laherparepvec or any of its excipients.
Bolniki, ki imajo v anamnezi preobčutljivost na talimogen laherparepvek ali katero od njegovih pomožnih snovi.
Patients with a history of ILD have not been studied.
Raziskave niso zajele bolnikov z IPB v anamnezi.
Patients with a history of malignancies in the gastrointestinal tract including the hepatobiliary system within the last five years.
Bolniki z anamnezo maligne bolezni prebavil v zadnjih petih letih, vključno z jetri, žolčnikom in žolčevodi.
Patients with a history of multiple drug allergies or significant hypersensitivity reactions may be at increased risk.
Tveganje je lahko večje pri bolnikih z anamnezo alergij na več zdravil ali izrazite preobčutljivosti.
patients with a history of neuroleptic malignant syndrome (a nervous system disorder usually caused by antipsychotic medicines) or rhabdomyolysis (breakdown of muscle fibres); patients taking medicines known as non-selective monoamine oxidase (MAO) inhibitors except when used to treat Parkinson’s disease.
bolnikih z anamnezo nevroleptičnega malignega sindroma (bolezni živčevja, ki jo običajno povzročijo antipsihotiki) ali rabdomiolize (razgradnje mišičnih vlaken); bolnikih, ki prejemajo zdravila, znana kot neselektivni zaviralci monoaminoksidaze (MAO), razen pri uporabi za zdravljenje Parkinsonove bolezni.
Patients with a history of seizures or other predisposing factors (see section 4.4) should be advised of the risk of driving or operating machines.
Bolnike z epileptičnimi napadi v anamnezi ali drugimi rizičnimi dejavniki (glejte poglavje 4.4) je potrebno seznaniti glede tveganja za vožnjo ali upravljanja s stroji.
Patients with a history of severe congestive heart failure or clinically unstable cardiac disease were excluded from clinical studies and therefore the safety and efficacy of Dacogen in these patients has not been established.
Bolniki z anamnezo hudega kongestivnega srčnega popuščanja ali s klinično nestabilno boleznijo srca niso bili vključeni v klinične študije, zato varnost in učinkovitost uporabe zdravila Dacogen pri teh bolnikih nista ugotovljeni.
patients with a history of severe heart disease,
bolnikih z anamnezo hudega obolenja srca,
patients with a history of severe heart disease;
bolnikih z anamnezo hudega obolenja srca;
Patients with a history of severe or life-threatening hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see section 4.4).
Bolniki s preteklo hudo ali življenjsko nevarno preobčutljivostjo na zdravilno učinkovino ali na katero koli pomožno snov, navedeno v poglavju 6.1. (glejte poglavje 4.4).
Patients with a history of severe or life-threatening hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see section 4.4).
Bolniki z anamnezo hude ali smrtno nevarne preobčutljivosti na zdravilno učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1 (glejte poglavje 4.4).
Patients with a history of sulphonamide allergy may be at greater risk of skin reactions (see section 4.3).
Pri bolnikih z anamnezo alergije na sulfonamid, obstaja večje tveganje za pojav kožnih reakcij (glejte poglavje 4.3).
Patients with a kidney problem
Bolniki z ledvičnimi težavami
Patients with a known central nervous system tumour
Bolniki z znanim tumorjem centralnega živčnega sistema
Patients with a known significant or chronic bowel disease such as inflammatory bowel disease or malabsorption.
bolniki s potrjeno pomembno ali kronično črevesno boleznijo, kot je vnetna črevesna bolezen ali malabsorpcija;
Patients with a mild to moderate (Grade 1 or 2) skin adverse reaction may remain on ipilimumab therapy with symptomatic treatment (e.g. antihistamines).
Pri bolnikih z blagimi do zmernimi (stopnja 1 ali 2) neželenimi učinki na kožo se zdravljenje z ipilimumabom lahko nadaljuje ob sočasnem simptomatskem zdravljenju (npr. z antihistaminiki).
Patients with a percent predicted FEV1 below 40% were not included in the study of patients with CF with non-G551D gating mutations, study 5 (see section 5.1).
Bolniki z napovedanim FEV1 v odstotkih pod 40 % niso bili vključeni v študijo bolnikov s CF in z ne-G551D mutacijami spreminjanja prehodnosti, študijo 5 (glejte poglavje 5.1).
Patients with a platelet count of 100,000/mm3 to 200,000/mm3 before starting Jakavi had a higher frequency of grade 3 or 4 thrombocytopenia compared to patients with platelet count >200,000/mm3 (64.2% versus 38.5%).
Pri bolnikih, ki so imeli že pred zdravljenjem z zdravilom Jakavi število trombocitov od 100.000/mm3 do 200.000/mm3, je pogosteje prišlo do trombocitopenije stopnje 3 ali 4 kot pri bolnikih, ki so imeli število trombocitov >200.000/mm3 (64,2 % v primerjavi z 38,5 %).
Patients with a prior history of pathological gambling may be at increased risk and should be monitored carefully (see section 4.8).
Tveganje je lahko večje pri bolnikih, ki so v preteklosti že imeli težave s patološkim hazardiranjem, zato je treba te bolnike skrbno nadzorovati (glejte poglavje 4.8).
Patients with a prior history of pathological gambling may be at increased risk and should be monitored carefully (see section 4.8).
Tveganje je lahko večje pri bolnikih, ki so v preteklosti že imeli težave s patološkim hazardiranjem, zato je treba te skrbno spremljati (glejte poglavje 4.8).
Patients with a propensity to bleed (e.g. due to recent trauma, recent surgery, coagulation disorders, active or recent gastrointestinal bleeding).
Bolniki, nagnjeni h krvavitvam (npr. zaradi nedavne poškodbe, nedavne operacije, koagulacijskih motenj, aktivne ali nedavne gastrointestinalne krvavitve).
Patients with a QTc interval over 480 msec.
Bolniki z intervalom QTc, daljšim od 480 ms.
Patients with a recent history of lung infiltrates or pneumonia may be at higher risk.
Večje tveganje lahko obstaja pri bolnikih, ki so pred nedavnim imeli pljučne infiltrate ali pljučnico.
Patients with a recent history of myocardial infarction or stroke were excluded from this study.
Bolniki z miokardnim infarktom ali možgansko kapjo v nedavni anamnezi so bili iz te študije izključeni.
Patients with a recent history of peritonitis (within the last 3 months), significant gastric or hepatic disorders and patients with major gastrointestinal surgery have not been included in clinical studies with Velphoro.
Bolniki z nedavno anamnezo peritonitisa (v zadnjih 3 mesecih), večjimi težavami želodca ali jeter in bolniki po zahtevnejšem gastrointestinalnem kirurškem posegu niso bili vključeni v klinične študije uporabe zdravila Velphoro.